PTGS2 and Dysmenorrhea: A previous study has demonstrated that SZC can reduce serum COX-2 levels in patients with dysmenorrhea (73), but the RT−PCR results of this study revealed that PTGS2 mRNA expression was significantly elevated after SZC treatment.